Tremfya Market Report 2026

Tremfya Market Overview

• The Tremfya market growth in the historic period has been driven by increasing prevalence of psoriasis and psoriatic arthritis, clinical success of biologic therapies • Market expansion is supported by increasing demand for long-term inflammatory disease management, expansion of biologics into gastroenterology indications • Growth Driver: Rising Prevalence Of Autoimmune Diseases Driving Market Growth Due To Increased Need For Targeted Biologic Therapies • Market Trend: Regulatory Approvals Boost Market Potential With New Indications • North America was the largest region in 2025.

What Is Covered Under Tremfya Market?

Tremfya (guselkumab) is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. It works by inhibiting interleukin-23 (IL-23), a protein involved in the inflammatory processes of these conditions. Tremfya is administered via subcutaneous injection once every 8 weeks after initial loading doses. The main types of indication in tremfya are moderate-to-severe plaque psoriasis and active PSA. Moderate-to-severe plaque psoriasis is a chronic skin condition characterized by red, inflamed patches of skin covered with silvery scales. With various types of formulations, including subcutaneous injection and intravenous infusion, it distributed through hospital pharmacies and retail pharmacies. And it caters to various end users, such as adult patients and geriatric patients.

What Is The Tremfya Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for long-term inflammatory disease management, expansion of biologics into gastroenterology indications, rising preference for less frequent dosing regimens, growing investments in monoclonal antibody therapies, increasing focus on personalized immunology treatments. Major trends in the forecast period include increasing adoption of il-23 inhibitor therapies, growing demand for long-interval biologic treatments, expansion of autoimmune disease indications, rising use of subcutaneous biologic injections, enhanced focus on targeted immunomodulation.

Global Tremfya Market Segmentation

1) By Indication: Moderate-To-Severe Plaque Psoriasis, Active PsA 2) By Formulation: Subcutaneous Injection, Intravenous Infusion 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies 4) By End User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Tremfya Market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the tremfya market going forward. Autoimmune diseases refer to conditions in which the body's immune system mistakenly attacks its cells, tissues, or organs, perceiving them as foreign invaders. The rising prevalence of autoimmune diseases is due to genetic predisposition, environmental triggers, lifestyle changes, increased awareness, and improved diagnostic capabilities. Tremfya is a monoclonal antibody targeting interleukin-23 (IL-23) that helps manage autoimmune diseases by modulating the immune system's overactive response, reducing inflammation, and alleviating symptoms in conditions such as psoriasis and psoriatic arthritis. For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the tremfya industry. The increasing healthcare expenditure is expected to propel the growth of the tremfya market going forward. Healthcare expenditure refers to the total spending on medical services, products, and public health initiatives to maintain and improve health. The increase in healthcare expenditure is due to an aging population requiring more medical care and the growing prevalence of chronic diseases such as diabetes and heart conditions. Higher healthcare expenditure enhances access to advanced biologic therapies such as tremfya by improving reimbursement coverage, diagnosis rates, and patient affordability. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual.Therefore, increasing healthcare expenditure is driving the growth of the tremfya industry.

Key Players In The Global Tremfya Market

Major companies operating in the tremfya market are Johnson & Johnson

Global Tremfya Market Trends and Insights

Key pleayer operating in the tremfya market are gaining regulatory approvals to expand its treatment indications, such as for moderate-to-severe Crohn's disease, which broadens its patient base and market potential. Regulatory approvals refer to the official authorization granted by authorities such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA), allowing a drug to be marketed for specific uses after demonstrating its safety, efficacy, and quality. For instance, in September 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received FDA approval for TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis, marking it as the first dual-acting interleukin-23 inhibitor approved for this condition. The decision is based on positive results from the Phase 2b/3 QUASAR study, which showed that approximately 50% of patients achieved clinical remission after 44 weeks of treatment. TREMFYA targets interleukin-23, helping to normalize the inflammatory response in the colon.

Regional Insights

North America was the largest region in the tremfy market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Tremfya Market?

The tremfya market consists of sales of subcutaneous injection pens, pre-filled syringes, and vials for healthcare providers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tremfya Market Report 2026?

The tremfya market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tremfya industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.